EMA recommends BI's Pradaxa bleeding agent and Amgen's Kyprolis; Endo moves forward with Par buyout;

@FiercePharma: Investors trounce Aratana on dashed hopes for canine lymphoma drugs. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Proud to say my home state is like, basically, the champion of pumpkin-growing. Where America's pumpkins come from. More | Follow @CarlyHFierce

> The European Medicines Agency (EMA) has recommended accelerated approval of Praxbind, which can be used to control bleeding in patients taking Boehringer Ingelheim's blood thinner Pradaxa. Release

> The EMA has also recommended approval for Amgen's ($AMGN) Kyprolis to treat patients with relapsed multiple myeloma. Release

> The EMA also recommended approval of Vertex Pharmaceuticals' ($VRTX) orphan drug Orkambi for the treatment of cystic fibrosis. Release

> Endo ($ENDP) says it will promptly proceed with its buyout of Par Pharmaceutical after receiving notice of termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the U.S. Release

> Teva ($TEVA) says it has a deal to buy Gecko Health Innovations, a software company working with ways to help tired people with respiratory disease adhere to meds and manage their diseases. Release

Medical Device News

@FierceMedDev: ICYMI: Study: 3-D tissue marker helps improve breast cancer monitoring, aids recovery. Article | Follow @FierceMedDev

@VarunSaxena2: Four key medical device recalls of 2015. Feature | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: EU regulators crack down on Brazilian devicemaker for implant safety scare. Article | Follow @EmilyWFierce

> Pathway Genomics' direct-to-consumer cancer diagnostic earns FDA warning letter. Report

> Sientra off by more than 50% after it discloses CE mark suspension for its contract manufacturer. More

> FDA panel grills Bayer over Essure safety. Story

Biotech News

@FierceBiotech: ICYMI: Aduro adds checkpoint inhibitors to a 'breakthrough' mix in $32M buyout. Article | Follow @FierceBiotech

@JohnCFierce: Think the drug pricing issue is going away? Washington Post: The secret truth. Report | Follow @JohnCFierce

@DamianFierce: As a longtime appreciator of dumb corporate M&A codenames, "Project Potsticker" is a solid addition. Bloomberg story | Follow @DamianFierce

> Troubled GlaxoSmithKline to shutter R&D facility in France. Story

> Roche, Boehringer and Gilead line up for EU drug approvals. News

> AbbVie dumps Galapagos' arthritis drug and presses on with its own. Article

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.